期刊文献+

18^F-FDGPET—CT在评价弥漫大B细胞淋巴瘤早期化疗反应中的应用价值 被引量:4

Significance of 18^F-FDG PET-CT in monitoring early chemotherapy response in patients with diffuse large B-cell lymphoma
原文传递
导出
摘要 目的 探讨18^F-FDG PET-CT在评价弥漫大B细胞淋巴瘤(DLBCL)早期化疗反应中的应用价值.方法 56例DLBCL初诊患者,采用CHOP或R-CHOP方案化疗,分别于化疗前和化疗2个周期后进行18^F-FDG PET-CT检查.比较完全反应组(30例)、部分反应组(18例)和无反应组(8例)间的完全缓解率及每组化疗前后最大标准摄取值(SUVmax).结果 完全反应组、部分反应组和无反应组的完全缓解率分别为93.33%(28/30)、66.67%(12/18)和12.50%(1/8),三组间差异有统计学意义(x2=21.62,P<0.005).完全反应组的完全缓解率高于部分反应组(x^2=4.00,P< 0.05);完全反应组、部分反应组的完全缓解率高于无反应组(x^2=18.58,P<0.005;x^2=4.51,P<0.05).完全反应组化疗前SUVmax为19.00±5.03,化疗后PET-CT示所有病灶均消失;部分反应组化疗前SUVmax为17.18±4.68,明显高于化疗后的5.20±3.35,差异有统计学意义(t=14.32,P<0.001);无反应组化疗前SUVmax为16.63±6.49,与化疗后的13.81±5.95相比,差异无统计学意义(t=2.073 2,P>0.05).结论 18FFDGPET-CT在DLBCL化疗早期有助于预测化疗疗效. Objective To assess the value of 18^F-FDG PET-CT in monitoring early chemotherapy response in patients with diffuse large B-cell lymphoma (DLBCL).Methods 56 patients with DLBCL received 18^F-FDG PET-CT before and after 2 cycles of chemotherapy (CHOP or R-CHOP protocol).The patients were divided into 3 groups,including complete response group (30 cases),partial response group (18 cases) and no response group (8 cases).The x^2 test was performed on comparison of complete remission rate and the t test on SUVmax.Results Complete remission rate of complete response group,partial response group and no response group were 93.33 % (28/30),66.67 % (12/18),and 12.50 % (1/8),respectively (x^2 =21.62,P 〈 0.005).Complete remission rate of complete response group was higher than that of partial response group (x 2 =4.00,P 〈 0.05).Complete remission rates of complete response group and partial response group were higher than that of no response group (x2 =18.58,P 〈 0.005; x^2 =4.51,P 〈 0.05).A significant difference was observed in SUVmax of partial response group before and after chemotherapy (17.18±4.68 vs 5.20±3.35,t =14.32,P 〈 0.001) and no obvious difference was showed in SUVmax of no response group between before and after chemotherapy (16.63±6.49 vs 13.81±5.95,t =2.073 2,P 〉 0.05).Conclusion 18F-FDG PET-CT is very useful and helpful for predicting early chemotherapy response in DLBCL.
出处 《白血病.淋巴瘤》 CAS 2014年第6期354-357,共4页 Journal of Leukemia & Lymphoma
基金 山西省肿瘤医院院所基金(201107)
关键词 淋巴瘤 大B细胞 弥漫型 18^氟-脱氧葡萄糖 正电子发射型体层摄影术 Lymphoma, large B-cell, diffuse 18^F-FDG Positron-emission tomography
  • 相关文献

参考文献10

  • 1Ying ZT,Wang XJ,Song YQ,et al.Value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma[J].Zhonghua Xue Ye Xue Za Zhi,2012,33:810-813.
  • 2Fuertes S,Setoain X,Lopez-Guillermo A,et al.Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma[J].Eur J Nucl Med Mol Imaging,2013,40:496-504.
  • 3Ceriani L,Suriano S,Ruberto T,et al.18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma[J].Clin Nucl Med,2012,37:949-952.
  • 4Cheson BD,Pfistner B,Juweid ME,et al.Revised response criteria for malignant lymphoma[J].J Clin Oncol,2007,25:579-586.
  • 5Weiler-sagie M,Bushelev O,Epelbaum R,et al.18F-FDG avidity in lymphoma readdressed:a study of 766 patients[J].J Nucl Med,2010,51:25-30.
  • 6Cashen AF,Dehdashti F,Luo J,et al.18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma:poor predictive value of international harmonization project interpretation[J].J Nucl Med,2011,52:386-392.
  • 7Zinzani PL,Gandolfi L,Broccoli A,et al.Midtreatment 18F-fluorodeoxyglucose positron-emission tomogrraphy in aggrressive non-Hodgkin lymphoma[J].J Nucl Med,2011,117:1010-1018.
  • 8李洪生,吴湖炳,王全师,王巧愚,李葆元.^18F—FDG PET/CT评价弥漫性大B细胞淋巴瘤化疗中期的治疗反应[J].中华核医学杂志,2011,31(3):145-150. 被引量:12
  • 9吴湖炳,王全师,王明芳,李洪生,周文兰,叶香华,王巧愚.^18F-FDG PET/CT在自然杀伤/T细胞淋巴瘤显像诊断及分期中的应用[J].中华核医学杂志,2010,30(1):19-22. 被引量:12
  • 10Ngeow JY,Quek RH,Ng DC,et al.High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma[J].Ann Oncol,2009,20:1543-1547.

二级参考文献27

  • 1任贤灵,贾全凡,向光明,赵泽宇,徐开伦,杜文.34例结外NK/T细胞淋巴瘤鼻型临床分析[J].临床耳鼻咽喉头颈外科杂志,2007,21(8):361-362. 被引量:12
  • 2Suzuki R,Takeuchi K,Ohshima K,et al.Extranodal NK/T-cell lymphoma:diagnosis and treatment cues.Hematol Oncol,2008,26:66-72.
  • 3Al-Hakeem DA,Fedele S,Carlos R,et al.Extranodal NK/T-cell lymphoma,nasal type.Oral Oncol,2007,43:4-14.
  • 4Chan JKC,Sin VC,Wong KF,et al.Nonnasal lymphoma expressing the natural killer cell marker CD56:a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.Blood,1997,89:4501-4513.
  • 5Li YX,Fang H,Liu QF,et al.Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring.Blood,2008,112:3057-3064.
  • 6Wu X,Li P,Zhao J,et al.A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma,nasal type.Clin Oncol (R Coll Radioi),2008,20:619-625.
  • 7Allen-Auerbach M,de Vos S,Czernin J.The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.Radiol Clin North Am,2008,46:199-211.
  • 8Terasawa T,Nihashi T,Hotta T,et al.^18F-FDG PET for posttherspy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma:a systematic review.J Nucl Med,2008,49:13-21.
  • 9Chim CS,Ma SY,Au WY,et al.Primary nasal natural killer cell lymphoma:long-term treatment outcome and relationship with the international prognostic index.Blood,2004,103:216-221.
  • 10Suh C,Kang YK,Roh JL,et al.Prognostic value of tumor ^18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphoto of the head and neck.J Nucl Med,2008,49:1783-1789.

共引文献22

同被引文献31

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部